The supervisory board of the pharmaceutical company Farmak (Kyiv) has re-elected Volodymyr Kostiuk as Executive Director.
According to the company’s press service, the relevant decision was made on December 17.
As reported, JSC Farmak (Kyiv) over 2020 received net profit of about UAH 1.138 billion, which is almost 7.8% more than in 2019 (UAH 1.056 billion). Over 2019, Farmak received net profit of UAH 1.056 billion, which almost coincided with the figure for 2018 – UAH 1.05 billion; and over 2018, it increased its net profit by 25.16%.
Farmak is the leader in the pharmaceutical market with a 5.9% share in monetary terms. The company manufactures medicines in all fourteen therapeutic groups. The main directions are anti-cold, endocrine, gastroenterological, cardiovascular, and neurological portfolios. Every year Farmak introduces to the market about 20 new complex-component modern drugs, about 100 drugs are currently in development.
According to the State Register, the ultimate beneficial owner of Farmak is head of the supervisory board, Filya Zhebrovska, who owns 80% of the company’s shares.